<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01934478</url>
  </required_header>
  <id_info>
    <org_study_id>QCH20130823-2</org_study_id>
    <nct_id>NCT01934478</nct_id>
  </id_info>
  <brief_title>Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer</brief_title>
  <official_title>Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao Central Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would
      be changed from negative to positive by cancer irradiation with liner-accelerator at dose
      6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression
      in human breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Her2 changes during radiotherapy</measure>
    <time_frame>every week up to 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>biopsy is obtained by fine needle biopsy，Her2 is checked by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <eligibility>
    <study_pop>
      <textblock>
        study population is among advanced Chinese breast cancer patient.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological confirmed advanced breast cancer

          -  cancer sample can be obtained by fine needle biopsy

          -  IHC and FISH confirmed Her2 negative

          -  radiotherapy indication for local residual cancer

        Exclusion Criteria:

          -  no radiotherapy indication

          -  patient refuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ketao lan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Qingdao Health Bereau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>youxin ji, M.D.</last_name>
    <phone>86532-68665078</phone>
    <email>mdji001@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qingdao Central Hospital, Qingdao Cancer Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>youxin ji, M.D.</last_name>
      <phone>8653268665078</phone>
      <email>mdji001@gmail.com</email>
    </contact>
    <investigator>
      <last_name>ketao lan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>chunling zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>youxin ji, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>August 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao Central Hospital</investigator_affiliation>
    <investigator_full_name>Youxin Ji</investigator_full_name>
    <investigator_title>Chief, Department of Oncology</investigator_title>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>Human Epidermal Growth Factor 2 (Her2)</keyword>
  <keyword>irradiation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
